Tumour Immunology

肿瘤免疫学

• 批准号: MC_UU_00008/1
• 负责人: Vincenzo Cerundolo
• 金额: $ 348.88万
• 依托单位: University of Oxford
• 依托单位国家: 英国
• 项目类别: Intramural
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MC_UU_00008%2F1
• 关键词: Tumour; Immunology

We are pursuing several different lines of investigation with the common goal of improving treatment strategies for cancer. The ability of cancer cells to avoid destruction by the immune system means that as yet there is no effective treatment. We know that in several different types of cancer there are increased numbers of cells called myeloid suppressor cells (MDSC) that suppress the immune system, and therefore allow cancer cells to continue to grow and divide. We also know that another kind of immune cells - invariant natural killer T (iNKT) cells –monitor malignant cells and decrease the numbers of circulating MDSCs in melanoma patients, thus restoring the immune response to cancer cells. These iNKT cells are very important because they form a “bridge” between the part of the immune system that recognises foreign proteins and the part that destroys abnormal cells. By studying the behaviour of iNKT cells we aim to find ways of increasing their activity in a controlled way, and use them to “jump-start” immune responses to tumour cells. Our clinical trial program is presently translating preclinical findings into phase I and II clinical trials of cancer vaccine candidates.

我们正在进行几个不同的研究路线，共同的目标是改善癌症的治疗策略。癌细胞避免被免疫系统破坏的能力意味着到目前为止还没有有效的治疗方法。我们知道，在几种不同类型的癌症中，有数量增加的称为髓系抑制细胞(MDSC)的细胞抑制免疫系统，因此允许癌细胞继续生长和分裂。我们还知道，另一种免疫细胞-不变自然杀伤T细胞(INKT)-监控恶性细胞，减少黑色素瘤患者循环中MDSCs的数量，从而恢复对癌细胞的免疫反应。这些iNKT细胞非常重要，因为它们在免疫系统识别外来蛋白质的部分和破坏异常细胞的部分之间形成了一座“桥梁”。通过研究iNKT细胞的行为，我们的目标是找到以受控方式提高其活性的方法，并用它们来“启动”对肿瘤细胞的免疫反应。我们的临床试验计划目前正在将临床前的研究成果转化为候选癌症疫苗的I期和II期临床试验。

项目成果

M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza.

• DOI: 10.1172/jci.insight.91868
• 发表时间: 2017-04-06
• 期刊: JCI insight
• 影响因子: 8
• 作者: Cole SL;Dunning J;Kok WL;Benam KH;Benlahrech A;Repapi E;Martinez FO;Drumright L;Powell TJ;Bennett M;Elderfield R;Thomas C;MOSAIC investigators;Dong T;McCauley J;Liew FY;Taylor S;Zambon M;Barclay W;Cerundolo V;Openshaw PJ;McMichael AJ;Ho LP
• 通讯作者: Ho LP

Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy.

• DOI: 10.3389/fimmu.2017.01829
• 发表时间: 2017
• 期刊: Frontiers in immunology
• 影响因子: 7.3
• 作者: Bedard M;Salio M;Cerundolo V
• 通讯作者: Cerundolo V

Sterile activation of invariant natural killer T cells by ER-stressed antigen-presenting cells

• DOI: 10.1073/pnas.1910097116
• 发表时间: 2019-11-19
• 期刊: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
• 影响因子: 11.1
• 作者: Bedard, Melissa;Shrestha, Dilip;Cerundolo, Vincenzo
• 通讯作者: Cerundolo, Vincenzo